Funding agencies: This work was supported by The Michael J. Fox Foundation for Parkinson's Research.
Article first published online: 31 OCT 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 13, pages 1606–1611, November 2012
How to Cite
Sherer, T. B., Chowdhury, S., Peabody, K. and Brooks, D. W. (2012), Overcoming obstacles in Parkinson's disease. Mov. Disord., 27: 1606–1611. doi: 10.1002/mds.25260
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 27 NOV 2012
- Article first published online: 31 OCT 2012
- Manuscript Accepted: 27 SEP 2012
- Manuscript Revised: 28 AUG 2012
- Manuscript Received: 22 MAY 2012
- disease modification;
- clinical trial recruitment
Improved symptomatic and disease-modifying treatments are needed for Parkinson's disease (PD). Although significant advances have been made in the understanding of PD etiology, the translation of these discoveries into novel transformative therapies has been limited as a result of systemic challenges in PD drug development. Preclinical testing lacks clear standards and prioritization criteria for advancing therapies to the clinic. Clinical testing is marked by expensive, long, and uninformative studies. In parallel to these scientific challenges, funding of late-stage drug development has become increasingly scarce and risk averse. In this context, novel models of collaboration and funding are opening up new avenues for pursuing treatments. This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles. © 2012 Movement Disorder Society